An estimated 14−17% of hospitalized COVID-19 patients develop a severe form of the disease, requiring oxygen support and admission to the intensive care unit.Underlying medical conditions such as diabetes, chronic cardiac diseases, chronic kidney diseases, obesity, and some genetic predispositions contribute to the severity of COVID-19.
Becton, Dickinson and Company (BD) has completed a preliminary study investigating the impact of deep cold storage (-20°C and -40°C) on glass prefillable syringes (PFS).
As a result of strong business growth over the last few years – sample management specialists – Ziath has made a new strategic investment to further support its expanding international operations.
Nobelpharma has signed a license agreement for the use of ProBioGen’s AGE1.CR.pIX vaccine production platform to develop theirlead vaccine.
20/20 GeneSystems has launched its Clinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S.
Pureos Bioventures, a venture capital fund dedicated to support private biotech companies developing novel therapies, has appointed several venture partners to its team. The firsttime fund has US$205 million under management and has invested in 11 private biotech companies so far. In addition, Pureos is a partner at BaseLaunch, an incubator of biotech startups in […]
Uniqsis reports how researchers at the School of Chemistry, University of Bristol (UK) have successfully prepared bicyclic lactams in high overall yield and excellent purity, under flow through conditions, using a photochemical [2+2] cycloaddition followed by a thermal electrocyclic cascade.
Avacta Group, a clinical stage biopharmaceutical company developing cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has made new appointments to its Scientific Advisory Board (SAB),reflecting the progress ofthe Therapeutics Division and Avacta’s transition to a clinical stage company.
Agilent Technologies has signed a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions.
Porvair Sciences has installed new automated precision die-cutting equipmentthat has enabled a five-fold increase in its production capacity for porous plastic components. This major investment by the company is in response to a significant rise in demand from customers for precision components made from its high performance Vyon porous plastics.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.